...
首页> 外文期刊>Journal of ocular pharmacology and therapeutics: The official journal of the Association for Ocular Pharmacology and Therapeutics >Comparative in vitro antifungal susceptibility activity of amphotericin B versus amphotericin B methyl ester against Candida albicans ocular isolates
【24h】

Comparative in vitro antifungal susceptibility activity of amphotericin B versus amphotericin B methyl ester against Candida albicans ocular isolates

机译:两性霉素B与两性霉素B甲酯对白色念珠菌眼分离物的体外抗真菌药敏性比较

获取原文
获取原文并翻译 | 示例
           

摘要

Purpose: To compare in vitro susceptibility of amphotericin B (AMB) and amphotericin B methyl ester (AME) (a more soluble and less toxic formulation of AMB) against Candida albicans isolates recovered from human cases of endophthalmitis. Methods: The in vitro susceptibility of AMB and AME was determined for C. albicans isolates recovered from endophthalmitis (N=10) and for C. albicans ATCC reference strain 90028 using the Clinical and Laboratory Standards Institute M27-A2 (NCCLS/CLSI) broth dilution method. All isolates were obtained from samples of vitreous humor of patients with suspected endophthalmitis within the last 5 years at the Bascom Palmer Eye Institute, University of Miami Miller School of Medicine (Miami, FL). Results: The minimal inhibitory concentrations (MICs) of AME were equal to or lower than values for AMB in 7 of the 10 isolates; range: AME (0.125-1μg/mL) versus (0.5-1μg/mL) for AMB. The MIC90 value of both drugs was equal (1μg/mL). Compared with AMB, the minimal fungicidal concentrations (MFCs) of AME were equal to or lower in 8 of 10 isolates; range: AME (0.125-2μg/mL) versus AMB (0.25-4μg/mL). MFC90 values of AME (1μg/mL) was slightly superior to AMB (2μg/mL). The MIC of the quality control strain (ATCC ? 90028) was within an acceptable range. Conclusions: AME was equivalent to AMB in vitro against C. albicans. This formula may offer a slightly more efficient and less toxic formulation for the treatment of Candida endophthalmitis.
机译:目的:比较两性霉素B(AMB)和两性霉素B甲酯(AME)(一种更易溶且毒性较小的AMB制剂)对从人眼内膜炎病例中回收的白色念珠菌分离株的体外敏感性。方法:使用临床和实验室标准协会M27-A2(NCCLS / CLSI)肉汤测定AMB和AME在体外从眼内炎中分离出的白色念珠菌分离株(N = 10)和白色念珠菌ATCC参考菌株90028的敏感性。稀释方法。所有分离物均取自迈阿密米勒大学医学院(佛罗里达州迈阿密市)的Bascom Palmer眼科研究所最近5年内疑似眼内炎患者的玻璃体样本。结果:AME的最低抑菌浓度(MICs)等于或低于10株菌株中7株的AMB值;范围:AME(0.125-1μg/ mL)与AMB(0.5-1μg/ mL)的比较。两种药物的MIC90值均相等(1μg/ mL)。与AMB相比,AME的最低杀真菌浓度(MFCs)在10个菌株中有8个等于或更低。范围:AME(0.125-2μg/ mL)与AMB(0.25-4μg/ mL) AME90(1μg/ mL)的MFC90值略高于AMB(2μg/ mL)。质量控制菌株的MIC(ATCC≥90028)在可接受的范围内。结论:AME相当于体外抗白色念珠菌的AMB。该配方可为治疗念珠菌眼内炎提供更有效,毒性更低的配方。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号